PFE PFIZER INC
Pharmaceutical Preparations · NYSE · SEC CIK 78003 · Fiscal year ends 12/31
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.3%
TTM net income YoY-59.0%
TTM EPS YoY-59.3%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR-27.3%
Margins
Gross margin73.4%
Operating margin—
Net margin6.3%
FCF margin18.5%
EBITDA margin—
Returns
ROE4.4%
ROA2.0%
ROIC (approx.)—
Asset turnover0.31x
Leverage & solvency
Liabilities / assets56.3%
Debt / equity0.70x
Current ratio1.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.51x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B |
| Cost of revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B |
| Gross profit | $46.51B | $45.78B | $34.60B | $66.83B | $50.47B |
| R&D expense | $10.44B | $10.82B | $10.68B | $11.43B | $10.36B |
| SG&A expense | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B |
| Interest expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B |
| Pretax income | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B |
| Income tax | -$266.00M | -$28.00M | -$1.11B | $3.33B | $1.85B |
| Net income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B |
| EPS (basic) | 1.37 | 1.42 | 0.38 | 5.59 | 3.92 |
| EPS (diluted) | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 |
| Dividends declared per share | 1.72 | 1.69 | 1.65 | 1.61 | 1.57 |
| Weighted avg. shares (diluted) | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B |
| Balance sheet | |||||
| Cash & equivalents | $1.14B | $1.11B | $2.92B | $468.00M | $1.98B |
| Short-term investments | $9.18B | $10.88B | $4.40B | $18.74B | $22.01B |
| Receivables | $11.87B | $11.46B | $11.57B | $10.95B | $11.48B |
| Inventory | $10.65B | $10.85B | $10.19B | $8.98B | $9.06B |
| Current assets | $42.90B | $50.36B | $43.33B | $51.26B | $59.69B |
| PP&E, net | $19.32B | $18.39B | $18.94B | $16.27B | $14.88B |
| Goodwill | $71.26B | $68.53B | $67.78B | $51.38B | $49.21B |
| Intangibles | $53.73B | $55.41B | $64.90B | $43.37B | $25.15B |
| Total assets | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B |
| Current liabilities | $36.98B | $42.99B | $47.79B | $42.14B | $42.67B |
| Short-term debt | $3.15B | $6.95B | $10.35B | $2.94B | $2.24B |
| Long-term debt | $61.64B | $57.41B | $61.54B | $32.88B | $36.20B |
| Total debt | $64.80B | $64.35B | $71.89B | $35.83B | $38.44B |
| Total liabilities | $121.39B | $124.90B | $137.21B | $101.29B | $104.01B |
| Shareholders' equity | $86.48B | $88.20B | $89.01B | $95.66B | $77.20B |
| Net debt | $63.65B | $63.24B | $68.97B | $35.36B | $36.45B |
| Cash flow statement | |||||
| Operating cash flow | $11.70B | $12.74B | $8.70B | $29.27B | $32.58B |
| Capital expenditure | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B |
| Free cash flow | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B |
| Investing cash flow | -$1.35B | $2.65B | -$32.28B | -$15.78B | -$22.55B |
| Financing cash flow | -$10.30B | -$17.14B | $26.07B | -$14.83B | -$9.82B |
| Depreciation & amortization | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B |
| Stock-based compensation | $799.00M | $877.00M | $525.00M | $872.00M | $1.18B |
| Share buybacks | — | $0 | $0 | $2.00B | $0 |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.